Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) insider Meir Eini sold 5,000 shares of the firm’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $6.68, for a total transaction of $33,400.00. Following the transaction, the insider now directly owns 16,271 shares of the company’s stock, valued at approximately $108,690.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Meir Eini also recently made the following trade(s):

  • On Wednesday, January 10th, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The shares were sold at an average price of $6.05, for a total transaction of $30,250.00.
  • On Monday, January 8th, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The shares were sold at an average price of $6.17, for a total transaction of $30,850.00.
  • On Tuesday, January 2nd, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The shares were sold at an average price of $6.18, for a total transaction of $30,900.00.

Foamix Pharmaceuticals Ltd (FOMX) traded up $0.16 during mid-day trading on Thursday, hitting $6.40. 58,069 shares of the stock traded hands, compared to its average volume of 117,658. The company has a market capitalization of $242.19, a P/E ratio of -4.89 and a beta of 1.62. Foamix Pharmaceuticals Ltd has a 12-month low of $4.03 and a 12-month high of $11.11.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.03). The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $0.90 million. Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. Foamix Pharmaceuticals’s revenue was down 64.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.19) EPS. equities research analysts anticipate that Foamix Pharmaceuticals Ltd will post -1.35 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in FOMX. Bank of New York Mellon Corp raised its stake in Foamix Pharmaceuticals by 38.6% during the second quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after buying an additional 151,849 shares during the last quarter. PDT Partners LLC bought a new position in Foamix Pharmaceuticals during the second quarter worth $304,000. Wells Fargo & Company MN raised its stake in Foamix Pharmaceuticals by 1,738.5% during the third quarter. Wells Fargo & Company MN now owns 47,801 shares of the specialty pharmaceutical company’s stock worth $265,000 after buying an additional 45,201 shares during the last quarter. DAFNA Capital Management LLC raised its stake in Foamix Pharmaceuticals by 9.2% during the second quarter. DAFNA Capital Management LLC now owns 355,667 shares of the specialty pharmaceutical company’s stock worth $1,650,000 after buying an additional 30,000 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its stake in Foamix Pharmaceuticals by 1.6% during the second quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock worth $493,000 after buying an additional 1,633 shares during the last quarter. 57.43% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently issued reports on FOMX. HC Wainwright set a $12.00 price target on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, January 5th. Guggenheim reaffirmed a “buy” rating and set a $8.00 price target on shares of Foamix Pharmaceuticals in a research note on Thursday, December 14th. Finally, Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th.

WARNING: “Foamix Pharmaceuticals Ltd (FOMX) Insider Sells $33,400.00 in Stock” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://theolympiareport.com/2018/01/18/foamix-pharmaceuticals-ltd-fomx-insider-sells-33400-00-in-stock.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.